EGF, murine recombinant
Epidermal Growth Factor (EGF) was originally discovered in crude preparations of nerve growth factor prepared from mouse submaxillary glands as an activity that induced early eyelid opening, incisor eruption, hair growth inhibition, and stunting of growth when injected into newborn mice. It is prototypic of a family of growth factors that are derived from membrane-anchored precursors. All members of this family are characterized by the presence of at least one EGF structural unit (defined by the presence of a conserved 6 cysteine motif that forms three disulfide bonds) in their extracellular domain. EGF is initially synthesized as a 130 kDa precursor transmembrane protein containing 9 EGF units. The mature soluble EGF sequence corresponds to the EGF unit located proximal to the transmembrane domain. The membrane EGF precursor is capable of binding to the EGF receptor and was reported to be biologically active. Mature mouse EGF shares 70 % a.a. sequence identity with mature human EGF.
Reference:
1. Chevalier RL, Goyal S, Thornhill BA. 1999. J Urol, 162: 1532-6
2. Gehm BD, McAndrews JM, Jordan VC, et al. 2000. Mol Cell Endocrinol, 159: 53-62
3. Yang H, Sun X, Wang Z, et al. 2003. J Membr Biol, 194: 47-58
4. Cohen S. 2008. J Biol Chem, 283: 33793-7.
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rMuEGF as determined by LAL method.
|
Gene ID |
13645 |
|
Accession # |
P01132 |
|
Alternate Names |
Urogastrone, URG |
|
Source |
Escherichia coli. |
|
M.Wt |
Approximately 6.0 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids, including 3 intramolecular disulfide-bonds. |
|
AA Sequence |
NSYPGCPSSY DGYCLNGGVC MHIESLDSYT CNCVIGYSGD RCQTRDLRWW ELR |
|
Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
|
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
|
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
|
Shipping Condition |
Gel pack. |
|
Handling |
Centrifuge the vial prior to opening. |
|
Usage |
For Research Use Only! Not to be used in humans. |